Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotics as a Predictor of Relapse in Schizophrenia Spectrum Disorders: A 1-Year Pilot Study
Authors:
- 19 April 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 44 (6) , 805-810
Abstract
Background: Long-acting injectable antipsychotics (LAIs) have been shown to reduce acute episodes of schizophrenia spectrum disorders (SSDs). However, breakthrough relapses are frequent, possibly because of underdosing in clinical practice. In this framework, the advantages of therapeutic drug monitoring (TDM) may be overlooked. This study explored the association of low steady-state LAI levels with a higher risk of relapse in SSDs, despite the use of a licensed posology. Methods: Forty-eight clinically stable outpatients with SSD underwent LAI-TDM using liquid chromatography–mass spectrometry for routine observational purposes. Baseline anamnestic, pharmacological, and psychometric evaluations compared subjects with “under-range” versus “in-range” LAI serum levels; between-group comparisons for different LAI treatments were also performed. A binary logistic regression explored which baseline factors (age, sex, previous hospitalizations, psychopathology, specific LAI treatment, and underrange serum levels) predicted relapse during the next 12 months. Results: Baseline comparisons did not show significant between-group differences, except for a higher percentage of underrange values in individuals receiving olanzapine pamoate. A total of 10 patients (20.8%) relapsed during the follow-up; only underrange LAI levels predicted the event (odds ratio 0.03, 95% confidence interval 0.01–0.36; P = 0.005). Conclusions: Even if relapse remains as a multifactorial event, LAI-TDM may identify subjects at risk for this negative outcome, thus optimizing antipsychotic maintenance treatment in the context of precision medicine. The finding of underrange LAI plasma levels in real-world practice should prompt adequate monitoring of clinically stable outpatients to identify the early signs of psychopathological deterioration.Keywords
This publication has 47 references indexed in Scilit:
- Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaPatient Preference and Adherence, 2013
- Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategiesWorld Psychiatry, 2013
- Estimating Dopamine D2 Receptor Occupancy for Doses of 8 AntipsychoticsJournal of Clinical Psychopharmacology, 2013
- Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohortInternational Journal of Methods in Psychiatric Research, 2013
- The nature of relapse in schizophreniaBMC Psychiatry, 2013
- Definitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewAnnals of General Psychiatry, 2013
- Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain functionMolecular Psychiatry, 2012
- Differentiating moderate and severe depression using the Montgomery–Åsberg depression rating scale (MADRS)Journal of Affective Disorders, 2003
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A Rating Scale for Mania: Reliability, Validity and SensitivityThe British Journal of Psychiatry, 1978